Everolimus in immunosuppressive treatment after kidney transplantation in a patient with tuberous sclerosis: case report.

Background: Tuberous sclerosis complex (TSC) is an inherited disorder caused by mutations of TSC1 or TSC2 genes, resulting in constitutive activation of the mammalian target of rapamycin (mTOR) and impairment of the cell cycle. As a consequence, hamartomatous tumors of multiple organs may develop, but generally skin, brain, kidneys, and lungs are involved. mTOR inhibitors (mTOR-I, rapamycin/everolimus) may correct underlying defects in TSC.

Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation.

Background: Recent studies have shown diabetogenic properties of calcineurin inhibitors, but the mechanism of more pronounced diabetogenic effect of tacrolimus (TAC) has not been completely elucidated. The study was designed to answer 2 questions: Does conversion from CyA to TAC influence tissue insulin sensitivity in patients after kidney transplantation? Are there any additional factors influencing insulin sensitivity in these patients?

Material/methods: Fifteen non-diabetic kidney transplant recipients, receiving CyA-based regimen were recruited to the study. Enrolled patients required conversion to TAC-based treatment due to CyA adverse effects.

Serum concentration of 1-84 (cyclase-activating) and 7-84 (cyclase-inhibiting) parathormone in elderly women with low mineral density of the trabecular bone.

Introduction: Ageing may cause an increase in parathormone (PTH) secretion and, subsequently, increased bone resorption and osteoporosis. In recent years two subfractions of PTH have been discovered: cyclase-activating (1-84, CAP) and cyclase-inhibiting (7-84, CIP) PTH. It is not known however, whether these may play a role in the pathogenesis of bone loss in elderly subjects.